# A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

> **NCT04998851** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 26 (actual)

## Conditions studied

- Multiple Sclerosis
- Clinically Isolated Syndrome

## Interventions

- **DRUG:** Ocrelizumab

## Key facts

- **NCT ID:** NCT04998851
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-16
- **Primary completion:** 2024-03-29
- **Final completion:** 2025-01-13
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04998851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04998851, "A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT04998851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*